Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYE National Vision	$23.37 +1.4%	$18.02	$9.56 ▼ $23.42	$1.85B	1.24	1.91 million shs	304,178 shs
LMAT LeMaitre Vascular	$82.68 +0.3%	$83.82	$71.42 ▼ $109.58	$1.87B	0.83	169,999 shs	32,477 shs
NVCR NovoCure	$17.33 +1.4%	$17.61	$14.17 ▼ $34.13	$1.93B	0.74	1.19 million shs	169,604 shs
RXST RxSight	$12.90 -2.5%	$14.66	$12.53 ▼ $60.81	$525.27M	1.29	706,298 shs	223,065 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYE National Vision	+0.04%	+0.26%	+21.30%	+79.88%	+83.16%
LMAT LeMaitre Vascular	-2.53%	+0.87%	-0.34%	-0.78%	+0.62%
NVCR NovoCure	-1.33%	+1.79%	-10.84%	-9.33%	-5.84%
RXST RxSight	+0.38%	-4.61%	-17.36%	-50.19%	-76.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYE National Vision	3.0359 of 5 stars	2.2	4.0	0.0	3.3	2.2	0.8	0.0
LMAT LeMaitre Vascular	2.808 of 5 stars	2.2	2.0	3.3	0.0	2.4	2.5	1.3
NVCR NovoCure	4.3255 of 5 stars	3.3	4.0	0.0	4.5	3.8	1.7	0.0
RXST RxSight	3.1859 of 5 stars	4.2	2.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYE National Vision	2.44	Hold	$18.67	-19.38% Downside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	19.13% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	91.58% Upside
RXST RxSight	2.30	Hold	$37.90	190.67% Upside

Current Analyst Ratings Breakdown

Latest RXST, NVCR, LMAT, and EYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00
5/19/2025	RXST RxSight	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$17.00 ➝ $25.00
5/12/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $17.00
5/9/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $17.00
5/9/2025	EYE National Vision	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$13.00 ➝ $21.00
5/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00
5/8/2025	EYE National Vision	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00
5/8/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$13.00 ➝ $15.00
5/7/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Buy
4/23/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$42.00 ➝ $34.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYE National Vision	$1.82B	1.00	$1.64 per share	14.09	$10.37 per share	2.23
LMAT LeMaitre Vascular	$219.86M	8.44	$2.32 per share	35.39	$15.00 per share	5.47
NVCR NovoCure	$605.22M	3.16	N/A	N/A	$3.33 per share	5.15
RXST RxSight	$139.93M	3.79	N/A	N/A	$6.98 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYE National Vision	-$28.50M	-$0.33	N/A	85.75	3.38	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$44.04M	$1.98	41.45	37.84	2.23	19.96%	13.53%	9.78%	7/30/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.67	N/A	N/A	N/A	-17.90%	-9.54%	-8.51%	8/4/2025 (Estimated)

Latest RXST, NVCR, LMAT, and EYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/7/2025	Q1 2025	RXST RxSight	-$0.03	-$0.03	N/A	-$0.20	$38.74 million	$37.90 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYE National Vision	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.97%	N/A	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Latest RXST, NVCR, LMAT, and EYE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYE National Vision	0.29	0.54	0.35
LMAT LeMaitre Vascular	0.48	16.49	13.83
NVCR NovoCure	0.27	1.47	1.41
RXST RxSight	N/A	12.68	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYE National Vision	N/A
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
EYE National Vision	2.70%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	5.52%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.45 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
RXST RxSight	220	40.64 million	36.75 million	Optionable

RXST, NVCR, LMAT, and EYE Headlines

Recent News About These Companies

SG Americas Securities LLC Buys Shares of 36,267 RxSight, Inc. (NASDAQ:RXST)

June 19, 2025 | marketbeat.com

FMS or RXST: Which Is the Better Value Stock Right Now?

June 18, 2025 | zacks.com

RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Hold" by Analysts

June 15, 2025 | marketbeat.com

RxSight (NASDAQ:RXST) Trading Down 5.6% - Here's Why

June 11, 2025 | marketbeat.com

RxSight: Valuation Blowout Creates Opportunity

June 7, 2025 | seekingalpha.com

RxSight (NASDAQ:RXST) Stock Price Down 5.5% - What's Next?

May 31, 2025 | marketbeat.com

RxSight, Inc. (NASDAQ:RXST) Shares Sold by Nuveen Asset Management LLC

May 31, 2025 | marketbeat.com

RxSight, Inc. (NASDAQ:RXST) Shares Sold by Two Sigma Investments LP

May 29, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Buys Shares of 46,700 RxSight, Inc. (NASDAQ:RXST)

May 28, 2025 | marketbeat.com

RxSight, Inc. (NASDAQ:RXST) Shares Sold by D. E. Shaw & Co. Inc.

May 28, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 74,800 Shares of RxSight, Inc. (NASDAQ:RXST)

May 27, 2025 | marketbeat.com

Royal Bank of Canada Raises Holdings in RxSight, Inc. (NASDAQ:RXST)

May 27, 2025 | marketbeat.com

Do Options Traders Know Something About RxSight Stock We Don't?

May 23, 2025 | msn.com

5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)

May 20, 2025 | benzinga.com

RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

May 20, 2025 | globenewswire.com

RxSight, Inc. (NASDAQ:RXST) Just Reported Earnings, And Analysts Cut Their Target Price

May 10, 2025 | finance.yahoo.com

Earnings call transcript: RxSight reports Q1 2025 earnings beat, stock rises 6.67%

May 9, 2025 | investing.com

RxSight, Inc. Reports 28% Revenue Growth in Q1 2025, Highlights Strong Demand for Light Adjustable Lenses

May 9, 2025 | nasdaq.com

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 9, 2025 | benzinga.com

RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Advances Amid ...

May 8, 2025 | finance.yahoo.com

RxSight, Inc. Reports Strong Q1 2025 Revenue Growth

May 8, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST, NVCR, LMAT, and EYE Company Descriptions

National Vision NASDAQ:EYE

$23.37 +0.31 (+1.35%)

As of 12:04 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

LeMaitre Vascular NASDAQ:LMAT

$82.68 +0.28 (+0.33%)

As of 12:03 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$17.33 +0.23 (+1.37%)

As of 12:04 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

RxSight NASDAQ:RXST

$12.90 -0.33 (-2.49%)

As of 12:03 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time